Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fruquintinib × S 1 (combination) × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 74 Pancreatic Neoplasms 24 Esophageal Squamous Cell Carcinoma 9 Esophageal Neoplasms 9 Colorectal Neoplasms 8 Neoplasm Metastasis 7 Biliary Tract Neoplasms 7 Nasopharyngeal Carcinoma 4 Colonic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Recurrence 3 Head and Neck Neoplasms 3 Cholangiocarcinoma 3 Advanced Pancreatic Cancer 3 Rectal Neoplasms 2 NSCLC 2 Locally Advanced Pancreatic Cancer 2 Gastrointestinal Neoplasms 2 Gastric Cancer Peritoneal Metastases 2 Advanced Gastric Cancer 2 Adenocarcinoma 2 mCRC 1 Surgically-Created Resection Cavity 1 Stage IV Gastric Cancer With Metastasis 1 Squamous Cell Carcinoma of Head and Neck 1 Progression Free Survival 1 Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1 Pancreatic cancer, adult 1 Pancreatic Ductal Adenocarcinoma 1 Pancreatic Adenocarcinoma 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡